



The CDC does not recommend repeating the maternal RSV vaccination if an expecting mother has received one in a previous pregnancy^{1*}

 **Beyfortus[®]** | 50 mg
(nirsevimab-alip) | 100 mg
Injection

Beyfortus is not indicated for adults.

Do you have expecting patients who have already received a maternal RSV vaccine? Talk to them about infant RSV disease prevention options

Beyfortus[®] is recommended by the CDC in instances where maternal vaccination is not recommended to be given.²

Beyfortus is recommended by the CDC for infants aged <8 months between October 1 and March 31.^{3†}

For full recommendations, please refer to the CDC website.

CDC, Centers for Disease Control and Prevention; **RSV**, respiratory syncytial virus.

*Current recommendations are if a pregnant woman has received a maternal RSV vaccine during a previous pregnancy, another dose of RSV vaccine is not recommended for subsequent pregnancies. Instead, the baby should receive a monoclonal antibody like Beyfortus.¹

†Timing of administration of RSV immunization may differ in certain areas.³

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information on the following page and accompanying full Prescribing Information.



Counsel expecting mothers about RSV antibodies such as Beyfortus® as an option for RSV disease protection⁴

With Beyfortus, infants receive protective antibodies against RSV disease starting Day 1 after injection. Beyfortus offers infants protection through 5 months, the typical length of RSV season.^{5-7*}

Beyfortus is not indicated for adults.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see additional Important Safety Information on the previous page and accompanying full Prescribing Information.



Your recommendation matters.
Learn more about Beyfortus at Beyfortus.com

*Based on clinical data.⁵

[†]Estimated absorption half-life following intramuscular injection from infant pharmacokinetic analysis was 1.7 days. Time to maximum concentration is 6 days in adults.^{5,6}

References: **1.** RSV vaccine guidance for pregnant women. Centers for Disease Control and Prevention. Updated August 30, 2024. Accessed November 12, 2025. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html> **2.** Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(41):1115-1122. **3.** Immunizations to protect infants. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed November 12, 2025. <https://www.cdc.gov/rsv/vaccines/protect-infants.html> **4.** Maternal respiratory syncytial virus vaccination. American College of Obstetricians and Gynecologists. Updated August 2025. Accessed November 12, 2025. <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccination> **5.** Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. **6.** Clegg L, Freshwater E, Leach A, et al. Population pharmacokinetics of nirsevimab in preterm and term infants. *J Clin Pharmacol.* 2024;64(5):555-567. **7.** Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. *J Infect Dis.* 2018;217(9):1356-1364.

sanofi

SANOFI
1 Discovery Drive, Swiftwater, PA 18370
© 2025 Sanofi. All rights reserved.
MAT-US-2513137-V1.0-11/2025

 **Beyfortus®**
(nirsevimab-alip) | 50 mg
100 mg
Injection